Dietary Supplements Access Act

On May 20, 2026, Senator Kevin Cramer (R-ND) introduced S.4587, the Dietary Supplements Access Act, which was read twice and referred to the Senate Committee on Finance. The bill amends the Internal Revenue Code to treat dietary supplements as qualified medical expenses for Health Savings Accounts (HSAs), Archer Medical Savings Accounts (MSAs), Health Flexible Spending Arrangements (FSAs), and Health Reimbursement Arrangements (HRAs), subject to an annual cap of $500 per individual ($250 for married filing separately). The effective date is for amounts paid or expenses incurred after December 31, 2026.

The money trail is straightforward: this is a tax expenditure, not a direct appropriation. The bill does not authorize any government spending; rather, it reduces tax revenue by allowing pre-tax dollars to be used for supplements. The Joint Committee on Taxation would estimate the revenue loss, but the bill text provides no specific dollar amount. The mechanism is a tax preference that lowers the after-tax cost of supplements for consumers with tax-advantaged health accounts.

Structural winners are pure-play dietary supplement companies whose primary revenue comes from products that qualify under the FDA definition of dietary supplements (excluding energy drinks, soft drinks, and soda). Nu Skin Enterprises ($NUS), Herbalife Nutrition ($HLF), USANA Health Sciences ($USNA), and GNC Holdings are the most directly exposed. These companies derive the majority of their revenue from dietary supplements sold through direct sales or retail channels. The $500 annual cap limits the per-individual benefit, but the aggregate effect across millions of HSA/FSA account holders could be significant. Diversified consumer health companies like Nestlé (which owns GNC) or Reckitt Benckiser have supplement exposure but as a smaller fraction of revenue.

The legislative path is early-stage. The bill has one cosponsor (Sen. Curtis, R-UT) and has been referred to the Finance Committee, which has jurisdiction over tax policy. No companion bill has been introduced in the House. The 119th Congress runs through January 2027, so the bill has time to advance, but committee markup and floor votes are required. The effective date of January 1, 2027, suggests the sponsors expect passage this year or early next. The bill's narrow scope (a tax code amendment with a clear effective date) makes it a plausible candidate for inclusion in a larger tax extenders package or health-related legislation.

No real market data was provided for supplement company stocks, so no price trend analysis is possible. However, the structural impact is clear: a tax subsidy for supplement purchases directly benefits companies with high supplement revenue exposure. The risk is legislative failure or delay, which would leave the status quo unchanged.